Mustang Bio, Inc

(NASDAQ:MBIO)

Latest On Mustang Bio, Inc (MBIO):

Date/Time Type Description Signal Details
2023-05-18 22:20 ESTNewsMustang to sell Worcester site for up to $11M, abandons some CAR T cell programsN/A
2023-05-13 01:40 ESTNewsMustang Bio GAAP EPS of -$2.06 beats by $0.95N/A
2023-04-03 23:45 ESTNewsMustang Bio announces 15-for-1 reverse stock splitN/A
2023-03-30 06:18 ESTNewsMustang Bio GAAP EPS of -$0.75 beats by $0.01N/A
2022-11-15 04:32 ESTNewsMustang Bio GAAP EPS of -$0.18 beats by $0.02N/A
2022-09-24 04:31 ESTNewsMustang Bio: This Horse May Gallop StillN/A
2022-08-17 20:47 ESTNewsMustang Bio (MBIO) Corporate Presentation - SlideshowN/A
2022-08-12 04:49 ESTNewsMustang Bio GAAP EPS of -$0.19 beats by $0.02N/A
2022-06-22 22:21 ESTNewsMustang Bio CAR T cell therapy for rare blood cancer gets FDA orphan drug statusN/A
2022-06-14 02:40 ESTNewsMustang Bio updates interim data for blood cancer candidateN/A
2022-05-20 00:40 ESTNewsMustang announces positive data from gene therapy trial to treat X-linked immunodeficiencyN/A
2022-05-12 19:50 ESTNewsMustang Bio GAAP EPS of -$0.20N/A
2022-05-03 17:16 ESTNewsMustang Bio: The Market Is Missing This OpportunityN/A
2022-04-13 19:41 ESTNewsMustang Bio plans to start phase 1 trial of combo therapy for brain cancerN/A
2022-03-24 16:27 ESTNewsMustang Bio GAAP EPS of -$0.76 misses by $0.03N/A
2022-03-24 16:26 ESTNewsMustang Bio surges as Cantor views 2022 “as a year for execution”N/A
2022-01-25 15:15 ESTNewsFDA puts on hold Mustang Bio's IND application for MB-207 in rare genetic disorderN/A
2022-01-25 15:14 ESTNewsMustang Bio down 9% following IND application hold, continuing rough yearN/A
2021-12-18 01:46 ESTNewsMustang Bio (MBIO) Investor Presentation - SlideshowN/A
2021-11-13 00:10 ESTNewsMustang Bio EPS misses by $0.01N/A
2021-11-01 23:11 ESTNewsMustang Bio shares rise 4% after $2M NIH grantN/A
2021-09-21 23:41 ESTNewsMustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal StudiesN/A
2021-08-16 20:48 ESTNewsMustang Bio EPS beats by $0.03N/A
2021-08-02 19:49 ESTNewsMustang Bio gets EMA Priority Medicines status for bubble boy disease treatmentN/A
2021-07-21 15:06 ESTNewsChecking Back In On Mustang BioN/A
2021-07-21 14:55 ESTNewsMustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancersN/A
2021-07-21 14:50 ESTNewsMustang Bio (MBIO) EHA Investor Presentations - SlideshowN/A
2021-03-24 21:14 ESTNewsMustang Bio EPS misses by $0.13N/A
2021-01-22 02:26 ESTNewsMustang Bio: Insider Buying Precedes 60% RallyN/A
2021-01-06 16:07 ESTFinancialsCompany financials have been released.Neutral
2020-12-22 05:16 ESTNewsMustang Bio launches early-stage CAR T therapy study in brain tumorN/A
2020-12-08 07:41 ESTNewsMustang Bio gains after impressing with ASH presentationN/A
2020-12-08 04:35 ESTAnalyst RatingThe Analyst Target Price has increased from $9 to $10.75.Buy
2020-11-26 20:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 04:32 ESTEarnings EstimateAn EPS average of -$0.26 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-07 16:25 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 12:11 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 11:52 ESTNewsMustang Bio EPS beats by $0.02N/A
2020-10-26 21:06 ESTNewsMustang Bio reports initial data on MB-105 in prostate cancerN/A
2020-10-06 16:19 ESTNewsMustang Bio in-licenses vector-enhancing technology for gene therapyN/A
2020-10-01 17:11 ESTNewsMustang Bio commences study of CAR T therapy in blood cancersN/A
2020-09-26 13:20 ESTFinancialsCompany financials have been released.Neutral
2020-09-19 16:31 ESTNewsMustang Bio's gene therapy an Orphan Drug in U.S. for immune system disorderN/A
2020-09-17 05:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-02 19:24 ESTNewsMustang Bio's MB-107 an Orphan Drug in the U.S. for rare genetic disorderN/A
2020-08-26 19:00 ESTNewsMustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy GoalsN/A
2020-08-18 13:23 ESTNewsMustang Bio lead drug nabs Rare Pediatric Disease tag for bubble boy diseaseN/A
2020-08-14 09:24 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 13:13 ESTFinancialsCompany financials have been released.Neutral
2020-08-11 18:23 ESTNewsMustang Bio EPS misses by $0.05N/A

About Mustang Bio, Inc (MBIO):

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.

MBIO Quotes by TradingView

See Advanced Chart

General

  • Name Mustang Bio, Inc
  • Symbol MBIO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 51
  • Fiscal Year EndDecember
  • IPO Date2017-08-22
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mustangbio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 3.01
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.25
  • Return on Assets -38%
  • Return on Equity -80%
  • Revenue -50000
  • Earnings Per Share -$1.33
  • Revenue Per Share $-0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 229.58 million
  • EBITDA -38426000
  • Analyst Target Price $10.75
  • Book Value Per Share $1.26
View More

Share Statistics

  • Shares Outstanding 64.75 million
  • Shares Float 50.5 million
  • % Held by Insiders 2242%
  • % Held by Institutions 26.32%
  • Shares Short 2.69 million
  • Shares Short Prior Month 2.99 million
  • Short Ratio 0.92
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.78
  • 52 Week High $5.22
  • 52 Week Low $1.97
  • 50 Day Moving Average 3.91
  • 200 Day Moving Average 3.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mustang Bio, Inc (MBIO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mustang Bio, Inc (MBIO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-06$N/A-$0.23-$0.244.17%
2020-06-302020-08-10$N/A-$0.32-$0.27-19.99%
2020-03-312020-05-11$N/A-$0.28-$0.318.71%
2019-12-312020-03-16$N/A-$0.41-$0.26-55.72%
2019-09-302019-11-12$N/A-$0.25-$0.275.66%
2019-06-302019-08-09$N/A-$0.29-$0.25-16%
2019-03-312019-05-10$N/A-$0.34-$0.378.11%
2018-12-312019-03-18$-50000-$0.44-$0.27-62.96%
2018-09-302018-11-13$N/A-$0.28-$0.25-12%
2018-06-302018-08-13$-50000-$0.19-$0.2524%
2018-03-312018-05-14$50000-$0.24-$0.23-4.35%
2017-12-312018-03-29$N/A-$0.61-$0.24-154.17%
2017-09-302017-11-14$N/A-$0.27

Mustang Bio, Inc (MBIO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 9.56 million 12.97 million 8.01 million
Income Before Tax N/A N/A -11.86 million -16.21 million -10.17 million
Selling General Administrative N/A N/A 1.96 million 2.95 million 1.99 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -10.85 million -15.92 million -10 million
Operating Income N/A N/A -11.52 million -15.92 million -10 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A -286000 -172000
Net Income From Continuing Operations N/A N/A -11.86 million -16.21 million -10.17 million
Net Income Applicable to Common Shares -12.95 million -14.6 million N/A -16.21 million -10.17 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -526000 N/A N/A
Change to Liabilities -1.04 million 2.18 million N/A 499000 76000
Total Cash Flow from Investing Activities -1.61 million -814000 N/A -1.39 million -899000
Net Borrowings -15.75 million N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 5.08 million N/A -111000
Change to Operating Activities -260000 1.74 million N/A 146000 -1.2 million
Change in Cash N/A N/A -5.6 million -10.88 million -9.84 million
Total Cash from Operating Activities -10.12 million -7.57 million -10.15 million -9.49 million -8.83 million
Depreciation N/A N/A 404000 381000 334000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 36000 73000
Other Cash Flow from Financing Activities -355000 -2.33 million N/A N/A -111000
Change to Net Income 1.34 million 3.27 million N/A 5.41 million 1.82 million
Capital Expenditures N/A N/A 526000 891000 499000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 22.76 million 21.79 million 21.39 million
Total Stockholder Equity N/A N/A 45.8 million 51.65 million 62.45 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A 68.56 million 73.45 million 83.84 million
Common Stock 5000 5000 N/A 4000 4000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -164.87 million -151.91 million -137.32 million -125.46 million -109.25 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 1.25 million 1.25 million N/A 1.25 million 750000
Cash N/A N/A 55.81 million 61.41 million 72.79 million
Total Current Liabilities 7.63 million N/A 10.04 million 7.77 million 6.29 million
Other Stockholder Equity 235000 N/A N/A 4.92 million N/A
Property, Plant & Equipment 9.19 million 9.31 million N/A 9.13 million 8.72 million
Total Current Assets 75.63 million N/A 57.71 million 63.06 million 74.36 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 76.42 million 71.03 million N/A 51.65 million 62.45 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A 10.56 million 12.18 million 13.19 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 7.05 million N/A 2.48 million 5.67 million 5.77 million

Mustang Bio, Inc (MBIO) Chart:

Mustang Bio, Inc (MBIO) News:

Below you will find a list of latest news for Mustang Bio, Inc (MBIO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mustang Bio, Inc (MBIO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest MBIO Trades:

Date Shares Price
Jun 13, 2022 7:52 PM EST100$0.586
Jun 13, 2022 7:52 PM EST400$0.5859
Jun 13, 2022 7:59 PM EST100$0.5939
Jun 13, 2022 7:59 PM EST62$0.5925
Jun 13, 2022 7:59 PM EST38$0.5925

Mustang Bio, Inc (MBIO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920075268/0001104659-20-075268-index.htm
2018-07-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680048/000000000018022168/0000000000-18-022168-index.htm
2019-08-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680048/000000000019012766/0000000000-19-012766-index.htm
2019-08-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680048/000000000019012768/0000000000-19-012768-index.htm
2019-09-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680048/000000000019013323/0000000000-19-013323-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465919062062/0001104659-19-062062-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000110465919062079/0001104659-19-062079-index.htm
2020-01-174/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920005207/0001104659-20-005207-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920005208/0001104659-20-005208-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920005209/0001104659-20-005209-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920005210/0001104659-20-005210-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920005211/0001104659-20-005211-index.htm
2020-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920005212/0001104659-20-005212-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1680048/000110465920034130/0001104659-20-034130-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920034139/0001104659-20-034139-index.htm
2020-04-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920052882/0001104659-20-052882-index.htm
2020-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920052883/0001104659-20-052883-index.htm
2020-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920052884/0001104659-20-052884-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920053522/0001104659-20-053522-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1680048/000110465920053524/0001104659-20-053524-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920059618/0001104659-20-059618-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000110465920059648/0001104659-20-059648-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920065513/0001104659-20-065513-index.htm
2020-06-04DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1680048/000110465920069666/0001104659-20-069666-index.htm
2020-06-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1680048/000110465920072000/0001104659-20-072000-index.htm
2020-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1680048/000110465920072893/0001104659-20-072893-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920073151/0001104659-20-073151-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920073411/0001104659-20-073411-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920075268/0001104659-20-075268-index.htm
2020-07-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1680048/000110465920084869/0001104659-20-084869-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920086524/0001104659-20-086524-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920092788/0001104659-20-092788-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920096923/0001104659-20-096923-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920096924/0001104659-20-096924-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920096925/0001104659-20-096925-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920096926/0001104659-20-096926-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920096928/0001104659-20-096928-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920112229/0001104659-20-112229-index.htm
2020-10-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680048/000110465920117789/0001104659-20-117789-index.htm
2020-10-23PRE 14COther preliminary information statementshttps://www.sec.gov/Archives/edgar/data/1680048/000110465920117791/0001104659-20-117791-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000110465920122540/0001104659-20-122540-index.htm
2020-05-29PX14A6GNotice of exempt solicitation submitted by non-managementhttps://www.sec.gov/Archives/edgar/data/1680048/000114036120012672/0001140361-20-012672-index.htm
2017-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420417021777/0001144204-17-021777-index.htm
2017-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417023120/0001144204-17-023120-index.htm
2017-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420417027453/0001144204-17-027453-index.htm
2017-05-26SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1680048/000114420417029848/0001144204-17-029848-index.htm
2017-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420417031316/0001144204-17-031316-index.htm
2017-06-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417031581/0001144204-17-031581-index.htm
2017-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2017-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420417031962/0001144204-17-031962-index.htm
2017-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420417032335/0001144204-17-032335-index.htm
2017-06-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417035223/0001144204-17-035223-index.htm
2017-06-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417035224/0001144204-17-035224-index.htm
2017-06-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417035225/0001144204-17-035225-index.htm
2017-06-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417035228/0001144204-17-035228-index.htm
2017-06-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417035231/0001144204-17-035231-index.htm
2017-07-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417037552/0001144204-17-037552-index.htm
2017-07-203/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417037554/0001144204-17-037554-index.htm
2017-07-203/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417037556/0001144204-17-037556-index.htm
2017-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420417042638/0001144204-17-042638-index.htm
2017-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420417043220/0001144204-17-043220-index.htm
2017-08-218-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1680048/000114420417044272/0001144204-17-044272-index.htm
2017-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420417054794/0001144204-17-054794-index.htm
2017-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420417058627/0001144204-17-058627-index.htm
2017-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420417058634/0001144204-17-058634-index.htm
2017-11-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420417058649/0001144204-17-058649-index.htm
2017-11-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1680048/000114420417061594/0001144204-17-061594-index.htm
2018-03-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1680048/000114420418017988/0001144204-18-017988-index.htm
2018-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420418018013/0001144204-18-018013-index.htm
2018-04-20PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1680048/000114420418021629/0001144204-18-021629-index.htm
2018-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1680048/000114420418023924/0001144204-18-023924-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420418028256/0001144204-18-028256-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420418028322/0001144204-18-028322-index.htm
2018-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420418034421/0001144204-18-034421-index.htm
2018-07-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680048/000114420418038364/0001144204-18-038364-index.htm
2018-07-20S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680048/000114420418039173/0001144204-18-039173-index.htm
2018-07-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680048/000114420418039176/0001144204-18-039176-index.htm
2018-07-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680048/000114420418039674/0001144204-18-039674-index.htm
2018-07-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1680048/000114420418040507/0001144204-18-040507-index.htm
2018-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420418040510/0001144204-18-040510-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420418044004/0001144204-18-044004-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420418044019/0001144204-18-044019-index.htm
2018-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420418057391/0001144204-18-057391-index.htm
2018-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420418058924/0001144204-18-058924-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420418059357/0001144204-18-059357-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420418059460/0001144204-18-059460-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420418061731/0001144204-18-061731-index.htm
2018-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420418062799/0001144204-18-062799-index.htm
2018-12-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420418063619/0001144204-18-063619-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000114420418065170/0001144204-18-065170-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1680048/000114420419014624/0001144204-19-014624-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420419014633/0001144204-19-014633-index.htm
2019-04-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420419018182/0001144204-19-018182-index.htm
2019-04-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1680048/000114420419021930/0001144204-19-021930-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1680048/000114420419022360/0001144204-19-022360-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1680048/000114420419022371/0001144204-19-022371-index.htm
2019-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420419022388/0001144204-19-022388-index.htm
2019-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1680048/000114420419022960/0001144204-19-022960-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420419025065/0001144204-19-025065-index.htm
2019-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420419025070/0001144204-19-025070-index.htm
2019-05-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1680048/000114420419027112/0001144204-19-027112-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420419031510/0001144204-19-031510-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000114420419038877/0001144204-19-038877-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420419038913/0001144204-19-038913-index.htm
2019-08-16PRE 14COther preliminary information statementshttps://www.sec.gov/Archives/edgar/data/1680048/000114420419040428/0001144204-19-040428-index.htm
2019-08-16S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680048/000114420419040430/0001144204-19-040430-index.htm
2019-08-30PRER14CInformation statementshttps://www.sec.gov/Archives/edgar/data/1680048/000114420419043050/0001144204-19-043050-index.htm
2019-08-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680048/000114420419043052/0001144204-19-043052-index.htm
2019-09-10DEF 14COther definitive information statementshttps://www.sec.gov/Archives/edgar/data/1680048/000114420419044167/0001144204-19-044167-index.htm
2019-09-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680048/000114420419046071/0001144204-19-046071-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680048/000114420419046520/0001144204-19-046520-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000155837020010205/0001558370-20-010205-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680048/000155837020013156/0001558370-20-013156-index.htm
2018-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1680048/000157104918000270/0001571049-18-000270-index.htm
2017-04-12DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680048/000168004817000004/0001680048-17-000004-index.htm
2018-07-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680048/999999999518001921/9999999995-18-001921-index.htm
2019-09-30EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680048/999999999519002209/9999999995-19-002209-index.htm
2017-08-21CERTNASCertification by the Nasdaq Stock Market approving securities for listinghttps://www.sec.gov/Archives/edgar/data/1680048/999999999717008165/9999999997-17-008165-index.htm
2017-09-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1680048/999999999717008908/9999999997-17-008908-index.htm
2017-11-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1680048/999999999717009967/9999999997-17-009967-index.htm

Mustang Bio, Inc (MBIO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Mustang Bio, Inc (MBIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2242%
Institutional Ownership: 2632%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-03-13Fortress Biotech, Inc.10% Share HolderBuy767,264.0010,131,053.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2017-03-31Fortress Biotech, Inc.10% Share HolderBuy1,600.0010,132,653.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2018-11-26Manuel MD LitchmanPresident and CEOBuy5,000.003.8719,353.5012,500.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418065170/0001144204-18-065170-index.htm
2020-03-26Brian AchenbachSVP, Fin. & Corp. ControllerBuy36,250.00129,274.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920052883/0001104659-20-052883-index.htm
2020-03-26Manuel MD LitchmanPresident and CEOBuy122,000.00155,000.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920052884/0001104659-20-052884-index.htm
2018-12-04Manuel MD LitchmanPresident and CEOBuy7,500.003.6027,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418065170/0001144204-18-065170-index.htm
2018-06-14MICHAEL S WEISSDirectorBuy10,000.0020,000.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920005209/0001104659-20-005209-index.htm
2020-05-14Manuel MD LitchmanPresident and CEOBuy90,000.002.79251,100.00245,000.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920065513/0001104659-20-065513-index.htm
2018-11-20Manuel MD LitchmanPresident and CEOBuy2,500.003.899,720.252,500.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418065170/0001144204-18-065170-index.htm
2018-12-10Manuel MD LitchmanPresident and CEOBuy8,000.003.3526,804.8028,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418065170/0001144204-18-065170-index.htm
2020-03-05Manuel MD LitchmanPresident and CEOBuy5,000.002.4812,400.0033,000.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920052884/0001104659-20-052884-index.htm
2020-05-21Manuel MD LitchmanPresident and CEOBuy90,000.003.13281,700.00335,000.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920065513/0001104659-20-065513-index.htm
2019-08-28MICHAEL S WEISSDirectorBuy13,812.0033,812.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920005209/0001104659-20-005209-index.htm
2020-06-11Manuel MD LitchmanPresident and CEOBuy153,846.003.25499,999.50488,846.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920073411/0001104659-20-073411-index.htm
2018-02-02Brian AchenbachVP, Fin. & Corp. ControllerBuy55,000.0055,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418062799/0001144204-18-062799-index.htm
2018-11-16Brian AchenbachVP, Fin. & Corp. ControllerBuy1,000.004.314,310.0056,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418062799/0001144204-18-062799-index.htm
2018-11-19Brian AchenbachVP, Fin. & Corp. ControllerBuy1,000.004.254,250.0057,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418062799/0001144204-18-062799-index.htm
2018-11-20Brian AchenbachVP, Fin. & Corp. ControllerBuy500.003.871,937.1057,500.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418062799/0001144204-18-062799-index.htm
2018-06-14Adam J. ChillDirectorBuy10,000.0060,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418058924/0001144204-18-058924-index.htm
2018-11-08Adam J. ChillDirectorBuy2,000.005.3410,680.0062,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418058924/0001144204-18-058924-index.htm
2018-11-12Adam J. ChillDirectorBuy1,000.004.854,850.0063,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418058924/0001144204-18-058924-index.htm
2018-11-02LINDSAY A MD ROSENWALDDirectorBuy50,000.004.41220,500.0070,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418057391/0001144204-18-057391-index.htm
2018-06-14Neil HerskowitzDirectorBuy10,000.0070,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418063619/0001144204-18-063619-index.htm
2018-11-23Neil HerskowitzDirectorBuy1,000.003.963,960.0071,000.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418063619/0001144204-18-063619-index.htm
2018-11-21Manuel MD LitchmanPresident and CEOBuy5,000.004.2121,048.007,500.00https://www.sec.gov/Archives/edgar/data/1680048/000114420418065170/0001144204-18-065170-index.htm
2019-08-28Adam J. ChillDirectorBuy13,812.0076,812.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920005210/0001104659-20-005210-index.htm
2019-08-28LINDSAY A MD ROSENWALDDirectorBuy13,812.0083,812.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920005208/0001104659-20-005208-index.htm
2019-08-28Neil HerskowitzDirectorBuy13,812.0084,812.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920005211/0001104659-20-005211-index.htm
2016-09-30Fortress Biotech, Inc.10% Share HolderBuy47,870.009,047,870.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2016-10-25Fortress Biotech, Inc.10% Share HolderBuy27,264.009,075,134.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2016-11-30Fortress Biotech, Inc.10% Share HolderBuy47,505.009,122,639.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2016-12-12Fortress Biotech, Inc.10% Share HolderBuy11,925.009,134,564.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2016-12-29Fortress Biotech, Inc.10% Share HolderBuy15,806.009,150,370.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm
2019-04-16Brian AchenbachSVP, Fin. & Corp. ControllerBuy35,000.0092,500.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920005212/0001104659-20-005212-index.htm
2020-03-05Brian AchenbachSVP, Fin. & Corp. ControllerBuy524.002.481,299.5293,024.00https://www.sec.gov/Archives/edgar/data/1680048/000110465920052883/0001104659-20-052883-index.htm
2017-01-31Fortress Biotech, Inc.10% Share HolderBuy213,419.009,363,789.00https://www.sec.gov/Archives/edgar/data/1680048/000114420417031582/0001144204-17-031582-index.htm